Biohit

Biohit Oyj is a publicly traded Finnish diagnostics company with a 35+ year legacy focused on preventing illnesses through innovative in vitro diagnostics. Its core achievement is the development and global commercialization of GastroPanel®, a blood test for stomach health assessment and gastric cancer risk stratification. The company's strategy centers on expanding the adoption of its proprietary tests in primary care settings and integrating them into national screening programs, leveraging its direct commercial subsidiaries in Italy and the UK.

Immunoassay-based platform for biomarker detection, centered on a proprietary algorithm interpreting four serum biomarkers (Pepsinogen I, Pepsinogen II, Gastrin-17, H. pylori IgG) to non-invasively assess stomach mucosa health and gastric cancer risk.

Operates in a niche segment where its integrated four-biomarker panel is a differentiated leader. Competes with standalone biomarker tests and broad-menu IVD giants. Competitive advantage stems from deep clinical validation, focused expertise, and direct commercial channels in key European markets.